Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 2NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 10Myeloid 6Thoracic 1Other solid neoplasm 1Lymphoid 1Classical hematology 1Breast 1

Conditions

Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Myelodysplastic Syndromes 1Leukemia, Myelomonocytic, Chronic 1Anemia, Refractory, with Excess of Blasts 1

Interventions

Cytarabine 13fludarabine phosphate 10Etoposide 8Methotrexate 7Cyclophosphamide 7Busulfan 7Idarubicin 6Daunorubicin 6tipifarnib 5Peripheral Blood Stem Cell Transplantation 5Filgrastim 5Cyclosporine 5Antilymphocyte Serum 5Vorinostat 4Tacrolimus 4Radiotherapy 4Mitoxantrone 4Lenalidomide 4Epoetin Alfa 4Azacitidine 4sargramostim 3merphos 3epoetin beta 3Topotecan 3Thioguanine 3Methylprednisolone 3Granulocyte-Macrophage Colony-Stimulating Factor 3Dexamethasone 3Decitabine 3Biopsy 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × decitabine and cedazuridine drug combination × Classical hematology × Clear all
NCT05600894 2026-05-13

Venetoclax in Combination With ASTX727 for the Treatment of Chronic Myelomonocytic Leukemia and Other Myelodysplastic Syndrome/Myeloproliferative Neoplasm

National Cancer Institute (NCI)

Phase 2 Active not recruiting
132 enrolled
Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Refractory, with Excess of Blasts, Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myelomonocytic, Chronic, Myelodysplastic-Myeloproliferative Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡